Saluda Medical

Saluda Medical is a pioneering healthcare startup that operates in the field of neuromodulation, specifically spinal cord stimulation (SCS). The company has developed a unique technology that measures the spinal cord's physiological response to stimulation, using Evoked Compound Action Potentials (ECAPs). ECAPs are electrical signals generated by the nervous system, and Saluda's technology allows for the first time, an objective measurement of these signals in the spinal cord.

The company's primary product is the Evoke® System, which uses ECAPs to provide smart neuromodulation therapy. This system listens and responds to each patient's unique neural signature, providing a more personalized and effective treatment. The Evoke® System has shown clinical superiority in a double-blinded, randomized clinical trial, demonstrating enduring patient outcomes.

Saluda Medical's business model revolves around providing this innovative technology to clinicians and healthcare providers. By offering a more objective and accurate measure of neural activation, the company empowers clinicians to provide more consistent pain relief to their patients. This is particularly important as neural activation is the mechanism that drives pain inhibition.

In terms of future potential, Saluda's proprietary SmartLoop™ technology could have broad applications in the field of neuromodulation, including therapies such as vagal nerve, sacral nerve, and deep brain stimulation. This suggests that the company has a significant growth potential in the expanding market of neuromodulation therapies.

Keywords: Neuromodulation, Spinal Cord Stimulation, Evoked Compound Action Potentials, Evoke® System, Neural Activation, Pain Relief, SmartLoop™ Technology, Healthcare Providers, Clinicians, Neural Signature.